Structural Formula

Physical Properties
Appearance: white crystalline powder
Density: 0.976±0.06
Melting point: <50°C
Boiling point: 615.9±30.0°C

Safety Data
Hazard category: General goods

Application
The combination of micro low calorie diet is suitable for the long-term treatment of obese and overweight people, including those who have developed obesity related risk factors. It has the effect of long-term weight control (weight loss, weight maintenance and rebound prevention). Taking the drug can reduce the incidence rate of obesity related risk factors and other obesity related diseases, including hypercholesterolemia and type 2 diabetes.

Orlistat is a non-CNS-acting agent for the treatment of obesity. It acts only in the gastrointestinal tract, preventing the hydrolysis of triacylglycerols into free fatty acids and monoacylglycerides by inhibiting lipase in the gastrointestinal tract, reducing the absorption of dietary fat (triacylglycerols) by the intestinal mucosa, and promoting the elimination of fat from the body. Lipase is an enzyme necessary for the decomposition of fat in the gastrointestinal tract. This product can combine with the serine residues of gastric and pancreatic lipase to inactivate lipase, so that it cannot decompose fat in food into free fatty acids and inhibit the utilization and absorption of fat.
Precautions: 1. Obese patients with type 2 diabetes mellitus lose weight after treatment with this product, often accompanied by improved glycemic control, and need to adjust hypoglycemic drugs to avoid hypoglycemia.
2. Pregnant and lactating women, children under 18 years of age and adolescents have not been studied for safety and efficacy, do not use.